Men still outnumber women four to one at the top of the FTSE-100 career ladder
Of the most senior full time jobs on the career ladder to chief executive, such as divisional or regional heads, only 21% are ...
GSK’s Withdrawn Blood Cancer Drug Reduced Risk of Death in Trial
GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...
MM&M1d
GSK launches gynecological cancer initiative after survey reveals care gaps
Despite significant medical advancements in the oncology space, 30% of patients in the GSK/Harris Poll survey said they never ...
BioPharma Dive1d
GSK partners with Flagship startup to hunt for Parkinson’s drugs
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...
GlaxoSmithKline (GSK) was downgraded to a Hold Rating at Jefferies
In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...
FiercePharma1d
GSK, with survey highlighting challenges facing gynecological cancer patients, kicks off initiative to close gaps in care
Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, ...
ENDPOINTS NEWS2d
GSK snags Parkin­son's drug from Flag­ship start­up Vesal­ius
GSK has licensed a small molecule for Parkinson's and is teaming up on additional targets for the disease and another ...
Bloomberg L.P.2d
GSK Steps Up Parkinson’s Focus With US Biotech Deal
GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...
Business Insider6d
Barclays Sticks to Their Hold Rating for GlaxoSmithKline (GSK)
GlaxoSmithKline ranks as one of the largest companies by total sales. The company wields its might across several therapeutic classes, including respiratory, oncology, and antiviral, as well as ...